Endonovo Therape Stock Price, News & Analysis

Endonovo Therapeutics (OTCQB: ENDV) has signed a binding Letter of Intent to spin off its medical device division into a new company, SofPulse, Inc., led by Ira Weisberg. The spin-off is contingent on due diligence and regulatory approvals. Ocean Tomo is conducting a valuation of SofPulse assets, with the last report valuing them at $75 million in 2018. Weisberg anticipates a pre-money valuation exceeding $50 million for SofPulse, which plans to focus on pain management solutions. Current shareholders will retain ownership in Endonovo without dilution. The new company aims to grow sales to over $100 million by 2024 and seeks NASDAQ listing.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced progress in obtaining Taiwan FDA approval for its flagship product, SofPulse^®, designed for pain management and recovery after surgery. This non-invasive device uses Pulsed Electro-Magnetic Field (PEMF) therapy to aid healing and reduce edema. Partnering with Evermed Medical Enterprises Co., a Taiwanese distributor, Endonovo aims to leverage Evermed's extensive network in Taiwan's healthcare market. Despite experiencing delays, the company is nearing final clearance and anticipates a positive reception for SofPulse^® in Taiwan, backed by strong clinical feedback and U.S. FDA certification.

Endonovo Therapeutics (OTCQB: ENDV) highlighted a success story involving Olympian surfer Carlos Muñoz, who recovered from a severe shoulder injury using the company's SofPulse^® device. Following invasive surgery, Muñoz experienced a significantly reduced recovery time, thanks to SofPulse^® Pulsed Electro Magnetic Frequency therapy, allowing him to return to competitive surfing in just nine months rather than the expected 18 months. Currently ranked 24th in the World Surf League, Muñoz aims to break into the top 10.

Endonovo Therapeutics (OTCQB: ENDV) has announced a new partnership with Academy Medical, establishing a Service-Disabled Veteran-Owned Small Business Government Reseller Agreement. The contract enables the distribution of SofPulse medical devices to the Veterans Health Administration and Department of Defense, aiming to enhance medical services for veterans. SofPulse devices are FDA cleared and designed to reduce postoperative pain and edema, facilitating better recovery while minimizing opioid use. The agreement represents a strategic move for Endonovo, allowing improved access to essential medical supplies and telehealth solutions for military personnel.

Endonovo Therapeutics (OTCQB: ENDV) announced a virtual Q&A session for shareholders on March 9, 2023, hosted by Ira Weisberg, President of the Medical Division. This session aims to discuss current and future plans, focusing on the company's proprietary SofPulse® PEMF technology, which is FDA cleared for post-surgical pain reduction. Weisberg's extensive experience is expected to enhance SofPulse®'s market presence. The agenda includes growth strategies, telehealth initiatives, and contracts with the U.S. Veterans Association. The company continues to innovate within the medical device sector, particularly in pain management and recovery.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) has engaged Ocean Tomo for a fairness opinion analysis to facilitate the spin-off of its medical device assets to a new entity, SofPulse, Inc. This analysis aims to determine the Fair Market Value of Endonovo’s medical device segment. The SofPulse medical device is designed to provide effective post-surgical pain relief and edema treatments. Ocean Tomo, known for its expertise in valuation and intellectual property, is expected to complete the analysis in Q1 2023. This engagement underscores Endonovo's commitment to shareholder interests as the company prepares necessary SEC filings following the spin-off.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) has entered a non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. to distribute its SofPulse^® medical devices in Mexico and Costa Rica. The Distributor has purchased over $100,000 of product for testing, followed by an initial order of $300,000. The Company anticipates significant quarterly revenue increases due to this partnership, supported by positive product feedback. Endonovo is also negotiating further distribution deals in South and Central America, Australia, Europe, and Southeast Asia, and expects Taiwan FDA clearance later in 2023.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced plans to spin off its medical device assets into a new company, SofPulse, Inc. This spin-off, expected in 2023, will allow SofPulse to operate independently, focusing on the commercialization of its medical device line and a newly introduced telehealth initiative. Endonovo anticipates a pre-money valuation of SofPulse exceeding $50 million, with approximately 20% of shares allocated to existing debtholders. Management aims to list SofPulse on NASDAQ, with a goal of achieving over $100 million in sales by the end of 2024.

Endonovo Therapeutics Inc. (OTCQB: ENDV) announced plans to spin off its medical device division, NewCo, into a separate publicly-traded entity. NewCo, led by Ira Weisberg, aims to advance medical device sales, focusing on wearable therapeutic devices and contracts with the Department of Defense and other markets. Meanwhile, Endonovo's M&A division, under CEO Alan Collier, targets profitable specialty construction firms, with a recent intent to acquire a company projected to generate over $50 million in revenue. The spin-off is expected to provide significant value to shareholders.